This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...

Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements ...

Early studies and preclinical modeling demonstrated sustained octreotide release, IGF-1 inhibition, and a safety profile consistent with approved SSAs. The first patient has been randomly assigned to ...

Palsonify is a medicine for certain people with acromegaly. Acromegaly is a rare disorder that happens when your body makes too much growth hormone (GH). This hormone is made and released in the ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript May 8, 2025 Crinetics Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.04 EPS, expectations ...

There are three main types of injectable weight loss drugs approved by the Food and Drug Administration (FDA): semaglutide, liraglutide and tirzepatide. These are administered either daily or weekly ...

Researchers at the Medical University of South Carolina revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a recent study ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced the launch of the first and only generic version of Sandostatin LAR Depot, in the United States.

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...